Expand AVIR Menu
AVIR MENU

AVIR Latest Press Releases

-- July 14, 2026 --

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus Globe Newswire 7:00 AM

-- June 25, 2026 --

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus Globe Newswire 7:00 AM

-- May 27, 2026 --

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 Globe Newswire 7:00 AM

-- May 13, 2026 --

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline Globe Newswire 7:00 AM

-- May 12, 2026 --

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- May 5, 2026 --

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 Globe Newswire 7:00 AM

-- March 24, 2026 --

ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO Business Wire 8:00 AM

-- March 5, 2026 --

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- February 26, 2026 --

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 Globe Newswire 7:00 AM

-- February 24, 2026 --

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes